Reacción a "A single once-daily pill combining two antiretrovirals simplifies HIV treatment, as demonstrated by a phase 3 trial"

This study shows that in patients receiving complex antiretroviral regimens with good immunovirological outcomes, switching to a once-daily single tablet of a new combination (islatravir/lenacapavir) achieves equivalent results, with improved acceptance due to the much simpler regimen.

It is a high-quality study involving a very large number of patients, although it does not represent a major advance compared with other once-daily single-tablet options already available on the market. Nevertheless, these two agents are new, highly potent, and very well tolerated, and they allow for long-acting formulations—that is, a single tablet taken once a week. In this context, which is already under investigation, it is clear that being able to take just one tablet per week would represent a very substantial improvement for eligible patients.